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Objective: There is little documentation of the effectiveness of percutaneous balloon angioplasty (PTA) of infrapopliteal
vessels for the treatment of chronic lower extremity ischemia. This study reviewed our recent experience with infrapop-
liteal PTA in a large series of patients to determine its effectiveness as a treatment modality.
Methods: All patients undergoing primary infrapopliteal PTA from March 2002 to June 2006 were included. Primary
study end points were primary patency, assisted patency, limb salvage, and patient survival assessed by Kaplan-Meier
life-table analysis. Factors predictive of PTA failure and patient longevity were evaluated by multivariate methods.
Results: There were 155 PTAs undertaken in 144 patients (70% men; mean age, 74 years), with critical limb ischemia
(86%), diabetes (66%), and renal insufficiency (45%). Infrapopliteal lesions were classified as TransAtlantic Inter-Society
Consensus A (7%), B (18%), C (39%), and D (35%). PTA was confined to the infrapopliteal segment in 40 (26%), and 115
(74%) underwent multilevel treatment. Five patients (3%) received stents. Technical success was 95%. The 30-day
mortality was 2%, and major morbidity was 3%. The mean follow-up was 22 months (range, 0-54 months). The
40-month actuarial primary patency was 62% (standard error, 5%), with assisted patency (infrapopliteal re-PTA, 25
[16%]) of 90%. Interval conversion to bypass surgery occurred in seven (5%). Nonhealing ulcers occurred in 118 patients
(76%), of which 76 (64%) healed during follow-up. Of the 42 unhealed ulcers, 15 (13%) required major amputations for
a 40-month limb salvage of 86.2%. Multivariate predictors that were negative for primary patency included 0/1 vessel
runoff (P  .01), critical limb ischemia (P  .002), and dialysis (P  .03). Negative predictors of limb salvage included
dialysis (P  .007) and failure to improve runoff to the foot (P  .006). At 40-months, patient survival was 54%, with
negative predictors including severe pulmonary disease (P  .01), coronary artery disease (P  .04), and renal
insufficiency (P < .001).
Conclusions: Infrapopliteal angioplasty can be performed safely with favorable results in patients with limited longevity.
Primary patency is related to disease extent. Secondary interventions may be necessary to maintain clinical success. These
data indicate that PTA should be considered as initial therapy for infrapopliteal occlusive disease in patients with lower
extremity ischemia. (J Vasc Surg 2009;50:799-805.)Chronic lower extremity ischemia due to atheroscle-
rotic disease remains a significant problem in the United
States, accounting for 400,000 hospitalizations and a
subsequent 20% mortality annually, mostly related to car-
diovascular events.1,2 As the population continues to age,
these numbers are expected to increase, with an estimated
10% to 20% of patients aged 70 years experiencing some
degree of chronic lower extremity ischemia.3 Patients with
critical limb ischemia (CLI) represent the most advanced of
these cases and often have disease affecting multiple levels
of arteries in the lower extremity, including the infrapopli-
teal vessels.
Early studies of percutaneous angioplasty (PTA) with
or without stenting of the tibioperoneal vessels reported
1-year patency rates of 15%, leading the authors to con-
clude this was suboptimal therapy that should be reserved
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doi:10.1016/j.jvs.2009.05.026for patients with no other options.4,5 Indeed, for patients
with CLI, surgical bypass grafting with autogenous conduit
remains the gold standard, with 5-year limb salvage rates
80%.6,7 However, a substantial portion of patients who
require arterial revascularization for CLI do not have an
adequate ipsilateral saphenous vein, and alternate conduits
with inferior patency and limb salvage rates must be
used.6,8 CLI also reflects an advanced, systemic form of
atherosclerotic disease that renders the patient at high risk
for complications after open surgical revascularization.9
In 2002 a more aggressive percutaneous approach of
revascularization for the treatment of infrainguinal occlu-
sive disease evolved in our group. This study evaluated the
midterm results of endovascular treatment of infrapopliteal
arterial disease in a contemporary series of patients with
chronic lower extremity ischemia. The primary end points
were primary and assisted patency, and secondary end
points included limb salvage and survival.
METHODS
Patients. All patients undergoing primary infrapopli-
teal PTA between March 2002 and June 2006 were iden-
tified. During the study interval, native infrapopliteal arte-
rial lesions in 155 limbs in 144 patients were treated with
PTA. The decision to use PTA as first-line therapy was
based on the clinical examination, anatomic evaluation, and
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from the evaluation were patients who presented with acute
CLI requiring emergency revascularization or who had a
functionally unsalvageable limb. Also excluded were pa-
tients who underwent PTA of threatened bypass grafts
(vein or prosthetic) or received mechanical thrombectomy,
atherectomy, or extended thrombolysis infusion. Individ-
ual limbs were counted separately so that patients under-
going staged, bilateral procedures were recorded and eval-
uated as two entries. This clinical protocol was approved by
the Institutional Review Board of the Massachusetts Gen-
eral Hospital.
Demographic, preoperative, perioperative, and postop-
erative data were collected for each patient. This included
clinical presentation according to the Rutherford classifica-
tion,10 lesion anatomy as defined by a modified TransAtlantic
Inter-Society Consensus (TASC) classification,11,12 and follow-
up ankle-brachial indices (ABI) or pulse volume recordings
(PVR), or both. Lesion characteristics were determined by
an examination of the procedure notes, and individual
images were reviewed when necessary. The modified TASC
classification for tibioperoneal occlusive disease is detailed
as follows:
● TASC A: a single stenosis 1 cm long.
● TASC B: multiple focal (1 cm) stenoses of the tibial
or peroneal arteries, including up to two focal stenoses
at the tibial trifurcation, or short tibial or peroneal
stenoses in conjunction with femoropopliteal disease.
● TASC C: Longer stenoses of 1 to 4 cm and occlusions
of 1 to 2 cm as well as extensive stenoses at the tibial
trifurcation.
● TASC D: occlusions 2 cm and diffusely diseased
tibial vessels.
If more than one tibial vessel was treated, the most
severe modified TASC classification was used.11,12
Renal insufficiency was defined as a serum creatinine
level 1.5 mg/dL. Patients were considered to have a
history of heart disease even if they had previously under-
gone revascularization with coronary artery angioplasty or
bypass grafting.
PTA procedure. All infrapopliteal PTAs were per-
formed in our fixed-imaging operating room suite or car-
diac catheterization laboratory by vascular surgeons who
satisfied Society for Vascular Surgery (SVS) criteria for
performance of endovascular procedures. Patients with pre-
operative renal insufficiency were routinely given oral ace-
tylcysteine and hydration with a bicarbonate solution be-
fore interventions.
Selective angiography was performed under local anes-
thesia through a contralateral retrograde or ipsilateral ante-
grade common femoral artery approach using 5F or 6F
sheaths. No popliteal punctures were used for vascular
access. Patients were given a weight-based dose of heparin
after the initial diagnostic arteriograms, and levels were
monitored with serial activated clotting times. Lesions were
crossed with platinum-tipped (0.018- or 0.014-inch) or
hydrophilic (0.035-, 0.018-, or 0.014-inch) wires, andballoon angioplasty was performed under systemic antico-
agulation. Subintimal angioplasty was not routinely used to
traverse occluded lesions.
Balloon catheter diameter was chosen to match the
nondiseased artery adjacent to the lesion, and tibial balloon
diameters ranged from 1.5 to 3 mm, whereas PTA of the
tibioperoneal trunk occasionally required a 4-mm balloon.
Indiscriminate use of long angioplasty balloons was
avoided to prevent adjacent arterial injury or dissection.
Balloon inflation pressures ranged from 4 to 12 atmo-
spheres and were held for at least 60 seconds. A selective
approach to the use of nitinol self-expanding stents was
used for flow-limiting dissections or when angioplasty
alone did not produce a satisfactory result (30% residual
stenosis).
Lesion anatomy was recorded by the operator for fur-
ther analysis, and lesions were then classified according to
the modified TASC criteria.11,12 All patients were given a
300-mg loading dose of clopidogrel after the procedure
and were maintained on 75 mg daily for 6 to 12 weeks.
Patients also received 325 mg of aspirin on the day of the
procedure, and this was continued indefinitely unless con-
traindicated. Sheaths were removed under manual com-
pression and closure devices were rarely used.
Postprocedure follow-up. Patients with ulcers were
treated and their lesions monitored. A noninvasive hemo-
dynamic assessment was routinely performed at 6 weeks
after the procedure, which included ABI and PVR. Studies
were repeated at 6-month intervals or when the patient’s
clinical condition dictated. Patients with noncompressible
vessels were most commonly assessed with PVR.
Patency was determined according to the Rutherford
guidelines,10 and patients who had a loss of distal pulses, a
return of symptoms or worsening ulceration, or a change in
ABI or PVR underwent further imaging. Follow-up also
involved a review of all outpatient clinic visits and hospital
admissions documented in our system-wide electronic
medical record.
Definitions and end points. PTA was considered an-
giographically successful when all technically accessible le-
sions were treated with a20% residual stenosis. Hemody-
namic success was defined as an ABI increase of at least 0.10
or improvement in PVR tracing by at least 5 mm for
patients with noncompressible vessels. Clinical success was
defined as an improvement of at least one clinical category
with demonstrable hemodynamic success for patients in
categories 1 to 4 and healing of the ulcer or wound in
categories 5 and 6 with confirmed improved hemodynam-
ics as defined by published reporting standards.10 A failure
of primary patency included patients who experienced a
decrease in ABI of0.10 or PVR5 mm due to recurrent
tibioperoneal disease, with or without a return of symptoms
by Rutherford reporting standards.10
Patients who experienced a return of symptoms that
was not secondary to tibioperoneal disease (ie, stenosis of
the femoropopliteal or iliac segments verified by angiogra-
phy) were considered clinical failures but not a loss of
primary patency. Assisted patency was achieved through
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gardless of whether the recurrent lesion was a restenosis,
occlusion, or a new lesion in the same anatomic segment.
Patency was considered to have failed in patients who
required surgical bypass, and they were not included in the
assisted patency calculations. Limb salvage and preservation
included all major amputations both above and below the
knee. Planned, staged digit amputations were not consid-
ered a failure of limb salvage. Survival data were obtained
from medical records and the Social Security database.
Statistical analysis. Patient demographic and risk fac-
tor data associated with intermediate patency and compar-
isons between the two cohorts were performed using 2
with or without Yates correction, Fisher exact test, t test,
and Mann-Whitney tests as appropriate. Actuarial patency
and survival analysis was performed using Kaplan-Meier life
tables with Mantel-Cox log-rank univariate analysis to
identify differences between groups. Relative risk, calcu-
lated as the risk ratio (RR) and 95% confidence intervals
(CI), were determined using a multivariate Cox propor-
tional hazards model for data with variable follow-up.
Multivariate models were constructed for each individual
outcome based on significant univariate variables. A value
of P  .05 was considered significant for all statistical
analysis.
RESULTS
During the study period, 144 patients underwent PTA
of 155 limbs. Of these, 22 procedures (14%) were per-
formed on patients with lifestyle-limiting claudication
(Rutherford classification 1 to 3) and 133 (86%) were
performed for CLI presenting as rest pain or tissue loss
(Table I). Demographic and clinical factors are summarized
in Table II. The mean serum creatinine level was 1.9
mg/dL. PTA was of the tibioperoneal arteries alone in 40
patients (26%). Multilevel treatment was required in 115
(74%), of whom 85 (55%) underwent concomitant PTA of
the above knee femoropopliteal segment (infrapopliteal
PTA in these patients was thought to be crucial to hemo-
dynamic success), and 21 of these lesions were occlusions.
The remaining 30 proximal lesions were confined to the
popliteal segment. Lesion characteristics and treatment fea-
tures are summarized in Table III.
Angiographic success, defined as the ability to cross and
dilate all significant lesions with20% residual stenosis, was
Table I. Clinical presentation of percutaneous
angioplasty (Rutherford classification)
Rutherford category No. (%)
1. Mild claudication 0 (0)
2. Moderate claudication 2 (1)
3. Severe claudication 20 (13)
4. Ischemic rest pain 17 (11)
5. Minor tissue loss 111 (72)
6. Major tissue loss 5 (3)achieved in 148 of 155 (95%) limbs. Five patients werenoted to have persistent, flow-limiting arterial dissections
that did not respond to repeat balloon inflations. These
were managed with balloon-expandable stents.
Complications. There were three (2%) periprocedural
deaths, two were secondary to aspiration pneumonia, and
the third occurred of an unknown cause after discharge.
Five patients (3%) experienced major procedurally related
complications during the study period. Groin hematomas
requiring blood transfusion developed in two patients, one
had a device malfunction with stent occlusion of the super-
ficial femoral artery requiring a bypass graft, Clostridium
difficile colitis developed in one patient, and one patient
experienced pulmonary edema requiring intubation for 24
hours. Minor complications included two small groin he-
matomas that were treated conservatively, two patients
with transient iodinated contrast-induced nephropathy,
and one patient with symptomatic microemboli to the toes
that was managed and resolved with analgesics. No mor-
bidity or mortality occurred in the patients who underwent
secondary PTA after primary failure.
Follow-up. Mean follow-up was 22 months (range,
Table II. Demographic and clinical data
Variable No (%) or average
Limbs, total 155
Demographics
Male gender 109 (63%)
Age, y 74 (43-100)
Risk factors
Hypertension 147 (94)
Heart disease 90 (58)
Diabetes 103 (66)
Renal insufficiencya 67 (44)
Dialysis 21 (14)
Current smoker 9 (6)
Previous smoker 90 (59)
Hyperlipidemia 98 (63)
Congestive heart failure 38 (25)
aDefined as serum creatinine 1.5 mg/dL.
Table III. Anatomic and treatment features
Variable No. (%), N  155
Modified TASC classification12
TASC A 11 (7)
TASC B 28 (18)
TASC C 61 (39)
TASC D 55 (36)
Angiographic findings
Multiple infrapopliteal vessels treated 85 (55)
Stent placed 5 (3)
Number of runoff vessels
0 3 (2)
1 70 (45)
2 68 (44)
3 14 (9)
TASC, TransAtlantic Inter-Society Consensus.0-54 months). The actuarial cumulative primary patency
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neal re-intervention) was 71.5%  4.4% at 24 months and
62% 5.5% at 40months (Fig 1). Variables associated with
failure to maintain primary patency by univariate analysis
included dialysis dependence (P  .005), failure to take
postprocedural clopidogrel (P  .003), CLI (P  .005),
TASCD lesions (P .04), 0/1 vessel runoff (P .02), and
failure to improve runoff to the foot (P .001; Appendix I,
online only). However, the multivariate model showed
failure to improve runoff to the foot (RR, 1.78; 95% CI,
1.07-2.74, P .03), 0/1 vessel runoff (RR, 1.55; 95% CI,
1.09-2.27, P  .01), CLI (RR, 11.43; 95% CI, not avail-
able; P .002), and dialysis (RR, 1.61; 95% CI, 1.05-2.37,
P  .03) were significant.
The assisted patency (maintained by redo PTA) was
90.4%  3.0% at 24 and 40 months with 25 (16%) infrap-
opliteal redo PTA (Fig 1). Factors predictive of failure to
maintain assisted patency by univariate analysis included
dialysis dependence (P .003), TASCD lesions (P .03),
and pulmonary disease (P .02; Appendix II, online only).
Multivariate analysis showed that dialysis dependence (RR,
2.71; 95% CI, 1.21-5.51; P  .02), pulmonary disease
(RR, 2.63; 95% CI, 1.31-5.1; P  .001), and TASC D
lesions (RR, 2.1; 95% CI, 1.1-4.55; P  .02) remained
significant.
Failures of primary patency occurred in 39 (25%) of the
155 procedures. Of these, 25 (16%) were managed with
repeat PTA, resulting in 15 arteries remaining patent and
10 failing again. Of the 10 that failed redo PTA, three
patients required primary major amputation, and four died
with no further intervention. The remaining three patients
underwent surgical bypass grafting leading to limb salvage
in two and eventual amputation in one. Five patients with
failure of primary patency underwent major amputation
without further attempts at intervention, and three patients
underwent surgical bypass with eventual amputation in
Fig 1. Kaplan-Meier curves comparing primary patency, assisted
patency and primary clinical improvement of patients undergoing
PTA of the infrapopliteal vessels.two. The remaining 6 patients were observed because ofcomorbidities. Five of these patients died of causes unre-
lated to the lower extremity occlusive disease. The ulcer in
the sixth patient healed before PTA failure and he is alive
and amputation-free.
The overall limb preservation rate was 86.2% 3% at 24
and 36 months, with no amputations occurring in the
claudication group. Significant univariate predictors of
limb loss included dialysis dependence (P  .001), failure
to take clopidogrel after the procedure (P .001), need for
proximal intervention (P  .004), multilevel treatment
(P  .007), and failure to improve runoff to the foot (P 
.001; Appendix III, online only). However, only dialysis
(RR, 2.4; 95% CI, 1.34-4.12, P  .004) and failure to
improve runoff (RR, 2.57; 95% CI, 1.37-4.56, P  .005)
remained significant in the multivariate model. Tissue loss
(Rutherford classification 5 and 6) occurred in 116 patients
(75%), of whom 76 (66%) showed major improvement or
complete healing during the follow-up period.
Overall survival was 68.3% 4% at 24months and 54%
5% at 40months (Fig 2). Multivariate negative predictors of
survival included CLI (P  .03), history of pulmonary
disease (P  .03), dialysis dependence (P  .001), history
of congestive heart failure (P  .001) and history of coro-
nary artery disease (P  .004; Appendix IV, online only).
Significant predictors identified by the multivariate model
included dialysis dependence (RR, 1.58; 95% CI, 1.14-
2.15; P  .008), pulmonary disease (RR, 1.45, 95% CI,
1.0-1.99, P .05), and congestive heart failure (RR, 1.69;
95% CI, 1.02-3.45, P  .04).
DISCUSSION
This study reviewed our experience with PTA of the
infrapopliteal vessels during a 4-year period. This time was
chosen because it marks a paradigm shift in the primary
management of infrainguinal occlusive disease from surgi-
Fig 2. Kaplan-Meier curves for survival and limb salvage of pa-
tients undergoing percutaneous angioplasty of the infrapopliteal
vessels.cal bypass to percutaneous revascularization. To date, this
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tients with midterm results, and several patients have now
been monitored for nearly 5 years. As expected, most
patients presented with CLI, and given the complexity of
vascular disease in this cohort, these results support the
continued use of PTA as the primary mode of revascular-
ization. Several elements of these results warrant further
discussion.
Infrapopliteal angioplasty has remained relatively under-
reported compared with PTA of femoropopliteal vessels,
partly due to early reports of limited technical success and
poor outcomes. Soder et al13 detailed their experience with
infrapopliteal PTA for limb salvage in 72 limbs and noted
an initial angiographic success rate of 61% in vessels with
occlusions and 18-month primary patency and limb salvage
rates of 48% and 80%, respectively. Similarly, Vraux et al14
reported a technical success rate of 78% in 40 patients
undergoing infrapopliteal PTA for CLI with a 1-year pri-
mary patency rate of 58%. Finally, Parsons et al4 performed
tibial PTA in 66 patients, and 1-year primary patency was
13%. These groups concluded that although infrapopliteal
PTA was feasible, the results did not justify a general
application to patient care.4
The application of smaller and more versatile coronary
balloon and wire systems to the peripheral vascular circula-
tion has fueled renewed interest in infrapopliteal PTA, and
several contemporary series have used these platforms. The
largest, by Bosiers et al,15 detailed infrapopliteal PTA in
443 patients with CLI and reported a 1-year primary pa-
tency of 74.2% and limb salvage rate of 96.6%, leading them
to predict that primary PTA would become first-line ther-
apy for CLI. Other smaller studies included 76 to 90
patients and reported primary patency rates of 68% to 74%
at 1 year.16,17 The 2-year primary patency in this study
compares favorably with these results, and the actuarial
40-month follow-up represents the longest in contempo-
rary literature.
A wide range of short-term primary patency rates of
tibial PTA has been reported, and these results compare
favorably. One reason for this may be that balloon dilation
of diseased arteries leads to activation of the inflammatory
response. It has been common practice to oversize balloons
and stents in the iliac and femoral vessels, and although
many reports state that “balloon diameters were chosen
based on the size of an adjacent normal artery,” it seems
logical that this would be applied to the infrapopliteal
vessels. Arterial overdistension is a well established model
of intimal hyperplasia, however,18,19 and it is possible that
the tibial vessels are more susceptible than other peripheral
vessels of the lower extremity.
During this study, it was the practice to approach tibial
vessel size and avoid over-distension. This is most often
accomplished by beginning with a small coronary balloon
(often 1.5 to 2 mm) as a reference and then upsizing as
appropriate. This occasionally results in a 2.5- to 3-mm
balloon, and no 4-mm balloons were used in the infrapop-
liteal vessels. Reports by Haider et al20 have detailed a
2-year primary patency of 60% in infrapopliteal vessels withthe use of 3- to 4-mm balloons, whereas Vraux et al21
reported using 3-mm balloons for all infrapopliteal arteries
with short (10- to 20-second), high-pressure (10- to 15-
atm) inflations that led to a primary patency of 46%.21
Siablis et al22 described oversizing tibial vessels by 0.5 mm
(which is at least 20%) during infrapopliteal stenting, with a
1-year in-stent primary patency of 30%. These results sug-
gest the importance of technique and balloon size on
outcomes, although further study regarding this is war-
ranted.
An alternative explanation of these results could be the
way primary patency was assessed. In this study, angio-
graphic follow-up to determine patency,22 as others have
reported, was not done and could not be justified. Only
patients with recurrent symptoms or hemodynamic deteri-
oration, as determined by a change in ABI, underwent
repeat imaging with angiography, whereas imaging was not
done in patients who remained clinically stable and had no
ABI changes. In addition, many of the clinical failures
resulted from progression of occlusive disease in other
vascular beds, which explains why the clinical success rate is
lower than the rate of primary patency (Fig 1).
Opponents of the use of PTA of the infrapopliteal
vessels as a primary treatment when anatomically feasible
have voiced the concern that failure could result in the need
for a more distal bypass or endovascular injury of target
vessels could result in the inability to identify a distal target
bypass for bypass. This was not identified in this cohort,
where surgical crossover was undertaken in primary and
secondary failures. However, Sanford et al23 detailed 66
patients who underwent surgical bypass for failed PTA,
including 16 tibial vessels (24%), and reported a 12-month
primary patency of 61%. They noted that 21% of patients in
the PTA failure group required a bypass more distal than
the original artery treated, emphasizing that the percutane-
ous procedure should be always be undertaken with con-
sideration of backup surgical options should the initial PTA
fail.
In this study, stents were selectively placed in the infr-
apopliteal vessels only when angioplasty yielded an inade-
quate result, which occurred in five patients. Tepe et al24
reported a 1-year restenosis rate of 29 % in 18 patients who
received self-expanding nitinol stents in the infrapopliteal
vessels for primary PTA failure. A pilot study from Austria
randomized 51 patients to primary PTA or PTA/stent
treatment of high-grade infrapopliteal lesions. They used
angiography to documented a 6-month primary patency
rate (70% restenosis threshold) of 83.7% for the stent group
and 61.1% for the PTA group (P .05) and concluded that
stents may be better than primary PTA in the short term.25
The application of drug-eluting stents to the infrapop-
liteal vessels has had mixed results in small series with
limited follow-up. In several studies Siablis et al22,26 re-
ported that drug-eluting stents were associated with a
significantly higher 1-year primary patency compared with
standard bare metal stents (odds ratio, 10.4; P  .001).
Regardless, the paucity of long-term follow-up data after
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lective use in patients with acute failure of primary PTA.
Although primary patency has been the benchmark by
which the success or futility of procedures for arterial
revascularization is determined, the real goal of therapy in
patients with CLI is ulcer healing and limb salvage. The
limb salvage rate after infrapopliteal PTA of 86% at 40
months in this report is comparable with that of femo-
rotibial bypass with autogenous vein and certainly better
than with prosthetic conduit.6,7 This has been supported
by others who have found that despite an inferior primary
patency, tibial PTA leads to limb salvage rates of 80% to
95% at 1 to 3 years.13,27-29
One reason that primary patency has been stressed in
the bypass literature is that graft failure can be the precipi-
tating event that ultimately leads to amputation.30 This has
not been the case with failed PTA, and indeed, the 40-
month assisted patency rate was 90% and the amputation
rate was 14% at 3 years. This supports the assertions that
failures of PTA often are amenable to repeat intervention,
and that many patients with CLI require a short-term
hemodynamic improvement to heal tissue loss.
Chronic renal failure with dialysis was the only demo-
graphic variable that remained a negative predictor
throughout all outcomes on multivariate analysis. This is
not surprising, because it reflects both the advanced disease
state in these patients and generalized systemic morbidity.
This finding of dialysis as a negative predictor is also iden-
tified in the lower extremity bypass literature, where some
have suggested that primary amputation is the most appro-
priate primary option in these patients.31 Aulivola et al16
compared infrapopliteal PTA for limb salvage in patients
with and without renal failure. They concluded that al-
though PTA is safe in this population, the poor rates for
wound healing and limb salvage bring to question its utility
in the infrapopliteal segment. The current study appears to
support this view.
The major limiting factor of this study remains its
retrospective nature, and continued prospective analysis of
PTA as first-line therapy for chronic lower extremity isch-
emia is necessary. In addition, all patients were treated at a
single institution, which opens the potential for selection
bias. Finally, although the follow-up on primary patency has
reached an intermediate level (mean 22months), follow-up
for assisted patency remains short, and inevitably, this value
will change with continued surveillance. However, the high
indigenous mortality rate in this patient population during
the 40-month study period suggests that many patients will
likely be managed solely with percutaneous interventions as
they die of their other comorbidities.
CONCLUSIONS
PTA of the infrapopliteal vessels can be performed
safely, with a low periprocedural morbidity and mortality.
Although intermediate primary patency rates do not match
those reported in the vein bypass literature, excellent as-
sisted patency and limb salvage can be achieved with close
follow-up and additional PTA if necessary. On the basis ofthese results, PTA should be considered initial therapy for
patients with CLI and severe claudication. Patients with
end-stage renal disease on dialysis have inferior patency,
limb salvage, and survival rates and should be treated with
PTA only after careful consideration.
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Variable
30-month primary patency
Coef PYes, % No, % P
Age 75 y 59 70 .41
Male gender 60 72 .13
Diabetes 63 66 .48
Current smoker 66 35 .79
Hypertension 64 67 .24
Congestive heart failure 60 66 .33
Dialysis 16 70 .005 1.61 .03
1/0 vessel runoff 53 78 .02 1.55 .01
Critical limb ischemia 57 100 .005 11.43 .002
TASC D 47 73 .04 1.32 .09
Clopidogrel 67 41 .003 1.51 .07
Hyperlipidemia 68 59 .31
Coronary artery disease 62 69 .24
Pulmonary 63 65 .89
Warfarin 62 66 .24
Renal insufficiency 53 70 .13
Proximal intervention 66 56 .22
TASC A 80 63 .10
TASC B 86 59 .10
TASC C 67 63 .75
Multilevel disease 67 54 .25
Improve runoff to foot 65 39 .001 1.78 .3
3 lesions 64 64 .88
3-vessel runoff 40 66 .65
TASC, TransAtlantic Inter-Society Consensus.
aUnivariate analysis performed through Kaplan-Meier life tables withWilcoxon signed rank test.Multivariate model based upon significant factors on univariate
analysis performed with Cox proportional hazards methods.
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Variable
30-month assisted patency
Coef PYes, % No. % P
Age 75 y 85 94 .7
Male gender 89 93 .37
Diabetes 91 90 .45
Current smoker 70 92 .15
Hypertension 90 100 .48
Congestive heart failure 83 92 .9
Dialysis 65 92 .03 2.71 .2
1/0 vessel runoff 89 92 .80
Critical limb ischemia 88 100 .14
TASC D 79 96 .3 2.11 .2
Clopidogrel 90 93 .61
Hyperlipidemia 88 95 .26
Coronary artery disease 85 96 .12
Pulmonary 60 94 .2 2.63 .09
Warfarin 97 88 .31
Renal insufficiency 88 92 .24
Proximal intervention 91 89 .44
TASC A 100 90 .34
TASC B 95 89 .56
TASC C 96 87 .30
Multilevel disease 90 93 .80
Improve runoff to foot 90 100 .47
3 lesions 89 96 .30
3-vessel runoff 80 92 .25
TASC, TransAtlantic Inter-Society Consensus.
aUnivariate analysis performed through Kaplan-Meier life tables withWilcoxon signed rank test.Multivariate model based upon significant factors on univariate
analysis performed with Cox proportional hazards methods.
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Variable
30-month limb salvage
Coef PYes, % No. % P
Age 75 78 93 .1 0.64 .9
Male gender 83 93 .22
Diabetes 82 94 .15
Current smoker 100 85 .26
Hypertension 86 86 .70
Congestive heart failure 84 87 .92
Dialysis 55 90 .01 2.15 .1
1/0 vessel runoff 82 92 .16
Critical limb ischemia 84 100 .6
TASC D 79 90 .29
Clopidogrel 90 58 .01 1.29 0.43
Hyperlipidemia 83 91 .58
Coronary artery disease 86 86 .97
Pulmonary 88 86 .92
Warfarin 84 87 .35
Renal insufficiency 85 87 .52
Proximal intervention 91 74 .04 1.08 0.90
TASC A 100 85 .22
TASC B 92 85 .48
TASC C 87 86 .84
Multilevel disease 90 75 .07 1.44 0.50
Improve runoff to foot 89 53 .01 2.50 .06
3 Lesions 89 78 .13
3-vessel runoff 100 85 .19
TASC, TransAtlantic Inter-Society Consensus.
aUnivariate analysis performed through Kaplan-Meier life tables withWilcoxon signed rank test.Multivariate model based upon significant factors on univariate
analysis performed with Cox proportional hazards methods.
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 4 Conrad et al 805.e4Appendix IV (online only). Analysis of variables affecting overall survivala
Variable
30-month survival
Coef PYes, % No. % P
Age 75 72 55 .06
Male gender 56 79 .08
Diabetes 58 72 .07
Current smoker 39 63 .81
Hypertension 62 73 .73
Congestive heart failure 43 69 .001 1.34 .06
Dialysis 26 68 .001 1.58 .008
1/0 vessel runoff 61 64 .41
Critical limb ischemia 59 82 .03 1.69 .04
TASC D 58 65 .64
Clopidogrel 64 53 .09
Hyperlipidemia 68 54 .26
CAD 49 78 .004 1.35 .06
Pulmonary 43 66 .03 1.45 .05
Warfarin 57 65 .12
Renal insufficiency 41 79 .001
Proximal intervention 61 66 .58
TASC A 83 60 .06
TASC B 62 63 .59
TASC C 60 64 .28
Multilevel disease 63 62 .90
Improve runoff to foot 63 50 .24
3 lesions 64 59 .94
3-vessel runoff 45 64 .56
TASC, TransAtlantic Inter-Society Consensus.
aUnivariate analysis performed through Kaplan-Meier life tables withWilcoxon signed rank test.Multivariate model based upon significant factors on univariate
analysis performed with Cox proportional hazards methods.
